Jul 26, 2022 | CMTRF Funded Research, Research news
By: Keith Fargo, PhD, Chief Science Officer New project will examine impact of two selective and potent drug candidates recently discovered by ORYZON The CMT Research Foundation is delighted to announce a new project with ORYZON, a clinical stage pharmaceutical...
Jul 26, 2022 | CMTRF Funded Research, Press Releases, Research news
CMTRF to provide funding for in vivo efficacy tests of Oryzon’s HDAC6 inhibitors in Charcot-Marie-Tooth preclinical model MADRID, SPAIN and Atlanta, July 26, 2022 Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company...
Jul 18, 2022 | CMT Research Updates, CMTRF Funded Research, Research news
By: Keith Fargo, PhD, Chief Science Officer CMT1B is one of the most common forms of CMT. In CMT1B, the part of the nervous system that is dysfunctional is the myelin sheath of the peripheral nerves. Created by cells called Schwann cells, myelin wraps around the parts...
Jul 11, 2022 | About CMT, CMT Research Updates, CMTRF Funded Research, Research news
By: Keith Fargo, PhD, Chief Scientific Officer We are happy to report that a CMTRF-funded project designed to test a PIKfyve inhibitor in CMT4B1, a particularly devastating form of the disease, has passed the first stage and is moving on to the next stage, a...
May 4, 2022 | CMT Research Updates, CMTRF Funded Research, News, Press Releases, Research news
By Keith Fargo, Chief Scientific Officer The CMT Research Foundation is pleased to announce that Shift Pharmaceuticals (Shift) has successfully completed their CMT Research Foundation-funded RNA-based therapy project. Shift created and tested a library of novel...
Mar 22, 2022 | About CMT, News, Research news
By Keith Fargo, Chief Scientific Officer At the CMT Research Foundation, we believe that more is achieved when people work together than when they work individually. This is especially true in biomedical research. Over the past few decades, a seismic shift has...
Important Research News Announcements